The final analysis of the Chemotherapy as Adjuvant for Locally Recurrent Breast Cancer (CALOR) trial33 showed that patients with ER-negative isolated locoregional BC recurrence had a statistically significant benefit from chemotherapy, whereas no benefit was detected for patients with ER-positive isolated locoregional BC recurrence. Here, ESR1 is linked to breast carcinoma.